Melanoma de alto riesgo reestadificado con F-18-FDG-PET/CT

Alejandro Martí  Samper

Authors

Alejandro Martí Samper Instituto Nacional de Cancerología

Keywords:

Positron emission tomography, Melanoma, Staging

Abstract Authors References How to Cite

Abstract

The melanoma is the most common form of deadly skin cancer, with an incidence that is increasing faster than any other type of potentially preventable cancer. The survival rates at five years for people with melanoma depends on the stage of the disease at diagnosis. Survival decreases as the thickness of the tumor and the stage of the disease increases. Most people with stage I lesions can expect disease free survival and even cure, while those with thicker lesions located in the more advanced stages are more likely to die from metastatic disease. Clinical, laboratory and imaging studies are needed to accurately stage these patients before definitive treatment. The use of diagnostic imaging such as positron emission tomography (PET) in patients at high risk provides an indispensable complement to the clinical staging.

Author Biography

Alejandro Martí Samper, Instituto Nacional de Cancerología

Grupo de Medicina Nuclear-PET, Instituto Nacional de Cancerología, Bogotá, Colombia

References

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.

https://doi.org/10.3322/caac.20138

Instituto Nacional de Cancerología. Anuario estadístico 2010. Bogotá: INC; 2012.

El-Maraghi RH, Kielar AZ. PET vs sentinel lymphnode biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. J Am CollRadiol. 2008;5:924- 31.

https://doi.org/10.1016/j.jacr.2008.02.022

Yancovitz M, Finelt N, Warycha MA. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110:1107-14.

https://doi.org/10.1002/cncr.22868

Sabel MS, Wong SL. Review of evidence-based support for pre- treatment imaging in melanoma. J Natl Compr Canc Netw. 2009;7:281-9.

https://doi.org/10.6004/jnccn.2009.0021

Bourgeois AC, Chang TT, Fish LM, Bradley YC. Positron Emission Tomography/Computed Tomography in Melanoma. Radiol Clin North Am. 2013;51:865-79.

https://doi.org/10.1016/j.rcl.2013.06.004

Iagaru A, Quon A, Johnson D. 2-Deoxy-2-[F-18] fluoro-D- glucose positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol. 2007;9: 50-7.

https://doi.org/10.1007/s11307-006-0065-0

Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:395- 407.

https://doi.org/10.6004/jnccn.2013.0055

Bronstein Y, Tummala S, Rohren E. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review. Clin Nucl Med. 2011;36: 96.

https://doi.org/10.1097/RLU.0b013e318203bb0e

Gulec SA, Faries MB, Lee CC, et al. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med. 2003;28:961- 5.

https://doi.org/10.1097/01.rlu.0000099805.36471.aa

Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004;10:262-70.

https://doi.org/10.1097/00130404-200407000-00007